I’ve spent enough years walking through pharmaceutical manufacturing facilities to notice something interesting. No one wakes up in the morning intending to make a poor-quality product.
No Quality Director plans to have a weak CAPA system.
No operator wants to contaminate a batch.
No executive hopes to receive an FDA Warning Letter.
Yet every year, FDA inspectors continue to find many of the same observations at companies around the world. Different products. Different facilities. Different leadership teams. But remarkably similar findings.
For a long time, I believed the industry’s biggest challenge was compliance.
I don’t anymore.
The real problem is much deeper.
The pharmaceutical industry has become more complicated than most organizations have evolved to handle.
Think about what we’ve asked companies to accomplish over the past decade.
Manufacture gene therapies, cell therapies, mRNA vaccines, monoclonal antibodies, highly potent compounds, and increasingly complex sterile products.
Implement electronic batch records.
Digitize laboratories.
Deploy Manufacturing Execution Systems.
Introduce artificial intelligence.
Expand globally.
Accelerate product launches.
Reduce costs.
Recover from supply chain disruptions.
Hire hundreds of new employees.
Transfer products between sites.
And somehow never make a mistake.
That’s an extraordinary expectation.
At the same time, many of the people who built this industry—the operators who could hear when a filling machine wasn’t quite right, the microbiologists who instinctively recognized contamination trends, the quality professionals who had lived through dozens of FDA inspections—are retiring. Their replacements are bright, motivated, and eager to learn.
But experience isn’t downloaded.
It has to be built. That is the capability gap quietly growing across our industry. Ironically, many organizations believe the answer is more technology. Another software platform.
Another dashboard. Another electronic quality system.
Another AI tool.
Technology is wonderful.
But technology has never fixed a weak process.
It simply performs that weak process faster.
If investigations fail to identify true root causes, AI will help you organize poor investigations more efficiently.
If operators don’t understand aseptic behavior, electronic training records won’t suddenly prevent first-air violations.
If quality culture is weak, digital signatures won’t create accountability.
Technology is an amplifier.
It makes good organizations better.
It also makes weak organizations fail faster.
That is why FDA’s expectations have quietly shifted over the past several years.
Inspectors aren’t impressed simply because procedures exist.
They want evidence that your quality system actually works.
Show them CAPAs that remain effective years later.
Show them investigations that uncover systemic weaknesses instead of blaming “human error.”
Show them trends that identified problems before patients were affected.
Show them a workforce that understands not just what to do—but why they’re doing it.
In other words, FDA is no longer inspecting paperwork.
They’re inspecting capability.
That distinction changes everything.
Because compliance is really just the byproduct of organizational capability.
Build capable people, and they build capable systems.
Build capable systems, and they produce consistent products.
Produce consistent products, and compliance becomes something you achieve—not something you chase.
Unfortunately, too many organizations still spend enormous amounts of money reacting.
Reacting to deviations.
Reacting to inspections.
Reacting to observations.
Reacting to Warning Letters.
Imagine if even a fraction of those resources were invested before the problems occurred.
Imagine building organizations where operators could recognize risk before compromising product.
Where supervisors identified weak signals before they became deviations.
Where investigations solved problems permanently instead of temporarily.
Where quality wasn’t owned by the Quality Unit—it was simply how everyone worked.
That’s where our industry has to go.
At Quality Executive Partners (QXP), we don’t believe sustainable compliance begins with writing another procedure. It begins with building capability throughout the organization.
Our Teach & Do® methodology allows us to work shoulder-to-shoulder with client teams, strengthening quality systems while transferring practical knowledge that remains long after we’ve left the site. Whether the challenge involves data integrity, laboratory operations, sterility assurance, manufacturing science, facility engineering, regulatory remediation, or inspection readiness, our goal isn’t simply to fix today’s problem—it’s to prevent tomorrow’s.
That’s also why we created Virtuosi®.
People don’t become experts because they sat through another PowerPoint presentation.
They become experts because they practice with no risk to product, the environment or to the patient.
They make decisions.
They problem solve.
They experience consequences.
They build confidence.
Virtuosi provides immersive learning experiences that allow pharmaceutical professionals to develop critical skills in realistic manufacturing environments before those decisions ever affect a patient or a commercial batch.
Because in the end, the pharmaceutical industry doesn’t need another quality system.
It needs better-equipped people operating better-designed systems.
Compliance will always matter.
But capability is what creates it.
If your organization is ready to move beyond reacting to compliance issues and begin building a culture of lasting operational excellence, QXP and Virtuosi are ready to help. Together, we help pharmaceutical companies strengthen quality systems, develop confident workforces, and build organizations that are prepared not only for their next FDA inspection—but for the future of pharmaceutical manufacturing itself.
Let’s talk!
QxP Vice President Christine Feaster is a 20+ year veteran in pharma quality assurance. Prior to joining QxP, Christine was a vice president of U.S. Pharmacopeia.
